Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQHWMJ)

Drug Name
LAM-003 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMQHWMJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Heat shock protein 90 (HSP90)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RNS-60 DMDNRU1 Asthma CA23 Phase 2 [3]
RTA 901 DMA6JME Diabetic neuropathy 8C0Z Phase 1 [4]
ADX-1612 DM86WI0 Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heat shock protein 90 (HSP90) TTO7FVG NOUNIPROTAC Inhibitor [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 Nov 26;3(22):3661-3673.
3 Clinical pipeline report, company report or official report of Revalesio.
4 Clinical pipeline report, company report or official report of Reata Pharmaceuticals.
5 Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2023 Mar 6;24(5):5014.